http://www.zibb.com/all/theme/cq/Insmed+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 23:13:52 GMTMon, 23 Nov 2009 23:13:52 GMT608831http://www.zibb.com/all/theme/cq/Insmed+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5688837/Insmed+Down+Since+SmarTrend+s+Sell+RecommendationSmarTrend, our proprietary pattern recognition system, called a Downtrend for Insmed (NASDAQ:INSM) on June 25, 2009 at $1.08. Since then, Insmed has returned 27.8% as of today's recent price of $0.78. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial. Writehttp://www.zibb.com/article/5688837/Insmed+Down+Since+SmarTrend+s+Sell+RecommendationInsmed IncorporatedMon, 23 Nov 2009 23:13:52 GMThttp://www.prnewswire.com/news-releases/insmed-announces-financial-results-for-third-quarter-and-nine-months-ended-september-30-2009-69362217.htmlInsmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009.http://www.prnewswire.com/news-releases/insmed-announces-financial-results-for-third-quarter-and-nine-months-ended-september-30-2009-69362217.htmlInsmed IncorporatedFri, 06 Nov 2009 12:00:00 GMThttp://seekingalpha.com/article/163714-insmed-is-well-positioned-to-make-a-good-deal?source=feedJae Jun submits: When you look hard enough and turn over enough stones, you are bound to find something sooner orhttp://seekingalpha.com/article/163714-insmed-is-well-positioned-to-make-a-good-deal?source=feedInsmed IncorporatedMon, 28 Sep 2009 18:42:50 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-16-2009/0005095523&EDATE=RICHMOND, Va., Sept. 16 /PRNewswire-FirstCall/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that on September 15, 2009 it received a NASDAQ Staff Deficiency Letter from The NASDAQ Stock Market.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-16-2009/0005095523&EDATE=Insmed IncorporatedWed, 16 Sep 2009 20:15:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=151819&full=1RICHMOND, Va., July 31 /PRNewswire/ -- Insmed Inc. (Nasdaq: INSM - News), a biopharmaceutical company, today announced that it will host a conference call on Thursday, August 13(th), at 8:30 AM ET, to discuss its financial results for the second quarter 2009. Insmed intends to issue its quarterlyhttp://www.biospace.com/news_story.aspx?StoryID=151819&full=1Insmed IncorporatedFri, 31 Jul 2009 12:00:00 GMThttp://finance.yahoo.com/news/Insmed-limits-supply-of-Iplex-apf-4237158202.html?x=0&.v=2RICHMOND, Va. (AP) -- Insmed Inc. said Monday it will no longer supply the drug Iplex to new patients because of limited inventory and the inabilityhttp://finance.yahoo.com/news/Insmed-limits-supply-of-Iplex-apf-4237158202.html?x=0&.v=2Insmed IncorporatedMon, 27 Jul 2009 15:05:59 GMThttp://www.pharmaceutical-business-review.com/news/insmed_provides_update_on_iplex_supply_090727Company has limited inventory on hand which must be conserved for the treatment of existing patientshttp://www.pharmaceutical-business-review.com/news/insmed_provides_update_on_iplex_supply_090727Insmed IncorporatedMon, 27 Jul 2009 00:00:00 GMThttp://www.icis.com/Articles/2009/03/16/9199484/the-biosimilars-market-continues-to-grow.htmlCynthia Challener/Vermont Once in doubt, the future of biosimilars is advancing along a path smoothed by European groundwork WITH an EU regulatory framework in place to address the safety of biosimilars - also known as follow-on biologics - thehttp://www.icis.com/Articles/2009/03/16/9199484/the-biosimilars-market-continues-to-grow.htmlInsmed IncorporatedMon, 16 Mar 2009 00:00:00 GMThttp://www.genengnews.com/news/bnitem.aspx?name=49531081Merck & Co. is offering $130 million for Insmed's pipeline of follow-on biologic (FOB) candidates and its commercial manufacturing facilities located in Boulder, CO. In Decembehttp://www.genengnews.com/news/bnitem.aspx?name=49531081Insmed IncorporatedThu, 12 Feb 2009 00:00:00 GMThttp://www.bizjournals.com/denver/stories/2008/10/13/daily8.html?ana=from_rssInformation technology integration company Ciber Inc. announced Monday that it expects its third-quarter revenue to be at the low end of its forecasts and that two acquisition deals it hopes to complete are being delayed by stock market volatility.http://www.bizjournals.com/denver/stories/2008/10/13/daily8.html?ana=from_rssInsmed IncorporatedMon, 13 Oct 2008 21:59:59 GMThttp://www.manufacturing.net/article.aspx?id=167544If Machinists vote to strike, Boeing could face potential losses as high as $100 million a day in deferred revenue and further delays in delivery of the new 787 commercial jet.http://www.manufacturing.net/article.aspx?id=167544Insmed IncorporatedWed, 03 Sep 2008 03:25:00 GMThttp://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/Todays Washington Post features a story on Ismed’s efforts to promote a follow-on biologics approval pathway here in Washington.  The article outlines the campaign by Insmeds chief exec, Geoffrey Allan, to give Congress a lesson in biotechnology.The sudden outpouring of educationalhttp://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/Insmed IncorporatedThu, 14 Aug 2008 02:10:00 GMThttp://www.washingtonpost.com/wp-dyn/content/article/2008/08/12/AR2008081203027.html?nav=rss_technologyCorrection to This Article Earlier versions of this article about generic drugs, in referring to Tylenol and its generic version, acetaminophen, referred to Tylenol as "the original product." Acetaminophen was approved as a drug before Tylenol was marketed as a brand name.http://www.washingtonpost.com/wp-dyn/content/article/2008/08/12/AR2008081203027.html?nav=rss_technologyInsmed IncorporatedWed, 13 Aug 2008 04:00:00 GMThttp://www.istockanalyst.com/article/viewarticle+articleid_2285870.htmlMerck Co. Inc.'s (MRK) results for the past several quarters were far above consensus expectations. Analysts have clearly under-estimated the power of what three new big drugs such as Vytorin (cholesterol), Januvia (diabetes), and Gardasil (cervical cancer vaccine) can do.The slide in saleshttp://www.istockanalyst.com/article/viewarticle+articleid_2285870.htmlInsmed IncorporatedFri, 13 Jun 2008 16:08:11 GMThttp://biopharminternational.findpharma.com/biopharm/News/Campaign-Promotes-Regulation-of-Follow-On-Biologic/ArticleStandard/Article/detail/491243?ref=25Insmed Inc. (Richmond, VA), has launched an education campaign about the importance of establishing a regulatory pathway in the US for large-molecule protein-based drugs, known as follow-on biologics (FOBs), biosimilars, or biogenerics.http://biopharminternational.findpharma.com/biopharm/News/Campaign-Promotes-Regulation-of-Follow-On-Biologic/ArticleStandard/Article/detail/491243?ref=25Insmed IncorporatedTue, 12 Feb 2008 05:00:00 GMThttp://www.cnbc.com/id/22950511/site/14081545?__source=yahoo|headline|quote|text|&par=yahooIt's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.http://www.cnbc.com/id/22950511/site/14081545?__source=yahoo|headline|quote|text|&par=yahooInsmed IncorporatedFri, 01 Feb 2008 15:51:43 GMThttp://www.dddmag.com/news-Merck-acquires-Insmed-biologics-021209.aspxMerck & Co., Inc. has agreed to purchase Insmed Inc.'s portfolio of follow-on biologic therapeutic candidates and its commercial manufacturing facilities located in Boulder, Colo.http://www.dddmag.com/news-Merck-acquires-Insmed-biologics-021209.aspxInsmed Incorporatedhttp://www.pharmpro.com/ShowPR~PUBCODE~021~ACCT~0000100~ISSUE~0902~RELTYPE~PR~ORIGRELTYPE~IN~PRODCODE~0000~PRODLETT~HW.htmlWHITEHOUSE STATION, N.J. (AP) - Merck & Co. said Thursday it will buy a slate of biotech drug candidates and a manufacturing facility from Insmed Inc. for $130 million. Insmed agreed to sell its pipeline ofhttp://www.pharmpro.com/ShowPR~PUBCODE~021~ACCT~0000100~ISSUE~0902~RELTYPE~PR~ORIGRELTYPE~IN~PRODCODE~0000~PRODLETT~HW.htmlInsmed Incorporatedhttp://www.bloomberg.com/apps/news?pid=20601202&sid=anuoqvyDio28&refer=healthcareMarch 10 (Bloomberg) -- Insmed Inc. will let Americans with the deadly and incurable nerve disorder Lou Gehrig’s disease try the “extremely limited” number of leftover vials of a growth drug pulled from the market in 2007 because of a patent dispute.http://www.bloomberg.com/apps/news?pid=20601202&sid=anuoqvyDio28&refer=healthcareInsmed Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=333886Mar. 11--The Food and Drug Administration announced Tuesday that some patients with a degenerative nerve disease will have access to a drug called Iplex, which has been unavailable to them since 2007.http://www.pharmacychoice.com/News/article.cfm?Article_ID=333886Insmed Incorporatedhttp://topics.nytimes.com/top/news/business/companies/insmed-inc/index.htmlGet Home Delivery Log In Register Now Home Page My Times Today's Paper Video Most Popular Times Topics Business All NYT New York Times Business World U.S. N.Y. / Region Business Media & Advertising World Business Small Business Your Money DealBook Markets Research Mutual Funds My Portfolio Alertshttp://topics.nytimes.com/top/news/business/companies/insmed-inc/index.htmlInsmed Incorporatedhttp://www.entrepreneur.com/tradejournals/article/print/189485379.htmlInsmed Inc. (Nasdaq: INSM), Richmond, Va., a developer of follow-on biologics and biopharmaceuticals, has reported results for the third quarter and nine-months ended September 30, 2008. Recent Company Highlights -- Follow-on Biologics Programhttp://www.entrepreneur.com/tradejournals/article/print/189485379.htmlInsmed Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={89117D27-4041-44A0-8139-0D4130A5A04C}&symb=IPSN.Y&sid=2820115RICHMOND, Va., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX/ -- Insmed Inc. (NASDAQ CM-D:INSM) , a developer of follow-on biologics and biopharmaceuticals, today announced that Genentech, Ipsen/Tercica and Insmed jointly issued the following statement:http://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={89117D27-4041-44A0-8139-0D4130A5A04C}&symb=IPSN.Y&sid=2820115Insmed Incorporatedhttp://www.authorizedmovers.com/articles/Longmont-LifeScience-Thursday-May-18.htm(PRWEB) May 12, 2006 -- The Longmont Area Economic Council (www.longmont.org), celebrating its 25th year, is proud to sponsor the Colorado BioScience Association's (CBSA) (www.cobioscience.com) Longmont LifeScience Thursday on May 18, 2006 from 3:30 p.m. until 6:00 p.m.http://www.authorizedmovers.com/articles/Longmont-LifeScience-Thursday-May-18.htmInsmed Incorporatedhttp://www.packagingtoday.co.uk/story.asp?storycode=32890Insmed has initiated a Phase II clinical trial examining the therapeutic benefit of treating HIV-associated Lipodystrophy with SomatoKine, the company's proprietary once daily IGF-I therapy.http://www.packagingtoday.co.uk/story.asp?storycode=32890Insmed Incorporated